There’s no shame in the bargain hunt when it comes to stocks. Although a low price per share in and of itself doesn’t mean a stock is a good investment. But that doesn’t mean it’s a bad price either.
Here are two low-cost stocks that long-term investors should consider buying right now.
1. Jushi Holdings
Trading for less than $6 per share at the time of writing this article. Jushi Holdings (OTC:JUSHF) It is a small company with serious long-term growth potential. The multi-state cannabis operator owns a family of cannabis brands including Tasteology, Nira, and The Lab Concentrates. It also has a network of cannabis retailers spread across Pennsylvania, Illinois, California and Virginia.
2020 was a highly profitable, high-growth year for Jushi Holdings, with revenues up nearly 700% and gross profits up 760% that were mouthwatering.
Jushi Holdings reported a 30 percent increase in revenue during the first quarter of 2021, but the company’s rapid growth has not hindered its ability to expand its cash position. It closed the period with a strong $168 million in cash or cash equivalents and short-term investments.
The company is also rapidly expanding its business in the country. In April alone, Jushi Holdings closed its acquisition of a cannabis manufacturing, manufacturing and distribution group in Nevada. In Ohio, the purchase of OhiGrow will give Jushi Holdings the ownership of one of only 34 licensed growers in the state, the official cannabis market. important doctor and in Massachusetts where marijuana is legal for both medical and recreational purposes, Jushi plans to acquire Nature’s Remedy, the plant and production plant owner. including two retail outlets
As Jushi Holdings continues to grow in the next few years. The balance sheet and the company’s share price will also increase significantly. This is a good time to grab the cheap share price of this premium pot stock to take advantage of its long-term potential.
Pfizer (NYSE:PFE) It rose to rock star status during the pandemic when BNT162b2, which was developed with the German allies. BioNTech — becoming a vaccine against COVID-19 The first to be approved for emergency use by the U.S. Food and Drug Administration. Despite the huge success of the BNT162b2, which is now marketed as the Comirnaty, not to mention the bulletproof portfolio of other lucrative products with strong sales growth, it’s still a huge success. Pfizer shares are still trading at less than $40.
Pfizer’s coronavirus vaccine is already having a significant impact on its balance sheet. The company expects to generate about $26 billion from Comirnaty in 2021 alone, and it recently announced on May 7 that it is filing with the FDA for it. The vaccine is fully approved for people aged 16 and over.
During the first quarter of 2021, Pfizer reported an astonishing 42% year-over-year revenue growth. but there are other products Many other than the coronavirus vaccine to rely on for future benefits. Even if you exclude the BNT162b2 factor from the image, The company continues to report excellent revenue growth of 8% year-over-year.
In addition to selling the coronavirus vaccine Pfizer’s strong core business expansion in the first quarter was also driven by consistent single- or double-digit revenue gains across core business segments, for example sales in oncology, internal medicine. and Pfizer’s rare diseases increased by 16%, 10%, and 25%, respectively. Among the top-selling drugs were the anticoagulants Eliquis, heart failure drugs Vyndaqel and Vyndamax, and arthritis drugs. Rheumatoid Xeljanz saw sales increase 25%, 88% and 18%, respectively. Management now forecasts full-year revenue in the $70.5 billion to $72.5 billion range.
Pfizer is also an attractive option for dividend-seeking investors. Stocks are yielding a good 4% at the time of writing this article. Moreover, it trades at a profit of just 20x. The combination of Pfizer’s affordable price tag and a mixture of growth and investor attractive value makes this stock a no-buy option in all conditions. market
This article expresses the opinions of the authors who may disagree with the recommendation’s position. The “official” version of Motley’s premium consulting service, we mix! Investment Thesis Questions Even our only story It helps us all think critically about investing and make decisions that make us smarter. happier and get richer